Rockwell Medical Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
48.4%projected annual EPS growth
Analyst Coverage
2analysts covering
FY Revenue (est.)
$72.5Mnext fiscal year
FY EPS (est.)
-$0.88next fiscal year
Monitoring Framework
Key Performance Indicators
Net Sales Quarterly17.3MTarget: 70000000 to 75000000
Gross Margin Quarterly17.0%Target: 18 to 22%
Adjusted EBITDA Quarterly-300KTarget: 1000000 to 2000000
Watch Items
- Nasdaq Minimum Bid Price ComplianceTrigger: Closing bid price below $1.00 for 30 consecutive business daysAction: Regain compliance by November 4, 2026, potentially utilizing the approved reverse stock split charter amendment.
- Customer Concentration and Volume ReductionsTrigger: DaVita sales concentration drop to 7% in Q1 2026 from 27% in 2025Action: Onboard new customers and implement pricing adjustments to offset volume reductions from major historical customers.
Research as of 20 Jun 2026